SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. )*
TransCode
Therapeutics, Inc.
(Name
of Issuer)
Common
Stock, par value $0.0001 per share
(Title
of Class of Securities)
89357L303
(CUSIP
Number)
July
23, 2024
(Date
of Event which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐
Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect
to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 89357L303 |
|
13G |
|
Page 2
of 8 Pages |
|
|
1. |
NAMES
OF REPORTING PERSONS
3i,
LP |
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☒
(b) ☐ |
3. |
SEC USE
ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware, United States |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE
VOTING POWER
0 |
6. |
SHARED
VOTING POWER
1,716,600
(1) |
7. |
SOLE
DISPOSITIVE POWER
0 |
8. |
SHARED
DISPOSITIVE POWER
1,716,600
(1) |
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,716,600
(1) |
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9%
(1) |
12. |
TYPE
OF REPORTING PERSON (see instructions)
PN |
(1)
As more fully described in Item 4 of this statement on Schedule 13G (this “Schedule 13G”), such shares
and percentage are based on 17,265,658 shares of common stock, par value $0.0001 per share, of the issuer (the “Common
Stock”), outstanding on July 24, 2024, as verified with the issuer.
CUSIP No. 89357L303 |
|
13G |
|
Page 3
of 8 Pages |
|
|
1. |
NAMES
OF REPORTING PERSONS
3i
Management LLC |
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☒
(b) ☐ |
3. |
SEC USE
ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware, United States |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE
VOTING POWER
0 |
6. |
SHARED
VOTING POWER
1,716,600
(1) |
7. |
SOLE
DISPOSITIVE POWER
0 |
8. |
SHARED
DISPOSITIVE POWER
1,716,600
(1) |
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,716,600
(1) |
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9% (1) |
12. |
TYPE
OF REPORTING PERSON (see instructions)
OO |
(1)
As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 17,265,658 shares of Common
Stock outstanding on July 24, 2024, as verified with the issuer.
CUSIP No. 89357L303 |
|
13G |
|
Page 4
of 8 Pages |
|
|
1. |
NAMES
OF REPORTING PERSONS
Maier Joshua Tarlow |
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☒
(b) ☐ |
3. |
SEC USE
ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
United States |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE
VOTING POWER
0 |
6. |
SHARED
VOTING POWER
1,716,600
(1) |
7. |
SOLE
DISPOSITIVE POWER
0 |
8. |
SHARED
DISPOSITIVE POWER
1,716,600
(1) |
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,716,600
(1) |
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9% (1) |
12. |
TYPE
OF REPORTING PERSON (see instructions)
IN |
(1)
As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 17,265,658 shares of Common
Stock outstanding on July 24, 2024, as verified with the issuer.
CUSIP No. 89357L303 |
|
13G |
|
Page 5
of 8 Pages |
Item
1(a). Name of Issuer:
TransCode
Therapeutics, Inc. (the “Issuer”).
Item
1(b). Address of Issuer’s Principal Executive Offices:
The
Issuer’s principal executive offices are located at 6 Liberty Square, #2382, Boston, MA 02109.
Item
2(a). Names of Persons Filing:
This Statement on Schedule 13G (the
“Schedule 13G”) is filed by: |
|
|
|
(i) |
3i, LP, a Delaware limited
partnership (“3i”); |
|
|
|
(ii) |
3i Management LLC, a Delaware limited liability
company (“3i Management”); and |
|
|
|
(iii) |
Maier Joshua Tarlow (“Mr. Tarlow”). |
The
foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons”. Any disclosures
herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the
appropriate party.
The
Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant
to which they have agreed to file this Schedule 13G and all subsequent amendments jointly in accordance with the provisions of
Rule 13d-1(k) of the Act.
The
filing of this Schedule 13G should not be construed in and of itself as an admission by any Reporting Person as to beneficial
ownership of the securities reported herein.
Item
2(b). Address of Principal Business Office or, if none, Residence:
The
principal business address of each of the Reporting Persons is 2 Wooster Street, 2nd Floor, New York, NY 10013.
Item
2(c). Citizenship:
3i
is a Delaware limited partnership. 3i Management is a Delaware limited liability company. Mr. Tarlow is a citizen of the United
States.
Item
2(d). Title of Class of Securities:
The
title of the class of securities to which this statement relates is the Issuer’s shares of common stock, par value $0.0001
per share (the “Common Stock”).
Item
2(e). CUSIP Number: 89357L303
CUSIP No. 89357L303 |
|
13G |
|
Page 6
of 8 Pages |
Item
3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is
a:
Not
applicable.
Item
4. Ownership.
The
information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages
to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported
are based on 17,265,658 shares of Common Stock outstanding, as verified with the Issuer on July 24, 2024.
3i
holds 1,716,600 shares of Common Stock (the “Shares”). 3i has the power to dispose of and the power to vote
the Shares beneficially owned by it, which power may be exercised by 3i Management, the manager and general partner of 3i. Mr.
Tarlow, as the manager of 3i Management, has shared power to vote and/or dispose of the Shares beneficially owned by each of 3i
and 3i Management. Mr. Tarlow does not directly own the Shares. By reason of the provisions of Rule 13d-3 of the Act, Mr.
Tarlow may be deemed to beneficially own the Shares beneficially owned by 3i and 3i Management, and 3i Management may be deemed
to beneficially own the Shares beneficially owned by 3i.
Item
5. Ownership of Five Percent or Less of a Class.
Not
applicable.
Item
6. Ownership of More than Five Percent on Behalf of Another Person.
Not
applicable.
Item
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not
applicable.
Item
8. Identification and Classification of Members of the Group.
See
Exhibit 1 filed herewith.
Item
9. Notice of Dissolution of Group.
Not
applicable.
Item
10. Certification.
By
signing below each of the Reporting Persons certify that, to the best of each of their knowledge and belief, the securities referred
to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having
that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
CUSIP No. 89357L303 |
|
13G |
|
Page 7
of 8 Pages |
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: July 26, 2024 |
3i, LP |
|
|
|
|
By: |
3i Management LLC, |
|
|
its General Partner |
|
|
|
|
By: |
/s/ Maier
J. Tarlow |
|
|
Name: Maier J. Tarlow |
|
|
Title: Manager |
|
|
|
|
3i Management LLC |
|
|
|
|
By: |
/s/ Maier
J. Tarlow |
|
|
Name: Maier J. Tarlow |
|
|
Title: Manager |
|
|
|
|
/s/
Maier J. Tarlow |
|
Maier J. Tarlow |
CUSIP No. 89357L303 |
|
13G |
|
Page 8
of 8 Pages |
EXHIBIT
1
JOINT
FILING AGREEMENT
PURSUANT
TO RULE 13d-1(k)
The
undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and
that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the
necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely
filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and
therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the
extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree
that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed
to be an original, but all of which counterparts shall together constitute one and the same instrument.
Date: July 26, 2024 |
3i, LP |
|
|
|
|
By: 3i Management LLC, |
|
its
General Partner |
|
|
|
|
By: |
/s/ Maier
J. Tarlow |
|
|
Name: Maier J. Tarlow |
|
|
Title: Manager |
|
|
|
|
3i Management LLC |
|
|
|
|
By: |
/s/ Maier
J. Tarlow |
|
|
Name: Maier J. Tarlow |
|
|
Title: Manager |
|
|
|
|
/s/
Maier J. Tarlow |
|
Maier J. Tarlow |
TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
From Nov 2024 to Dec 2024
TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
From Dec 2023 to Dec 2024